Amneal Pharmaceuticals (AMRX) Equity Ratio: 2017-2025
Historic Equity Ratio for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to -0.03.
- Amneal Pharmaceuticals' Equity Ratio fell 12.98% to -0.03 in Q3 2025 from the same period last year, while for Sep 2025 it was -0.03, marking a year-over-year decrease of 12.98%. This contributed to the annual value of -0.03 for FY2024, which is 642.75% down from last year.
- Per Amneal Pharmaceuticals' latest filing, its Equity Ratio stood at -0.03 for Q3 2025, which was up 7.10% from -0.03 recorded in Q2 2025.
- Over the past 5 years, Amneal Pharmaceuticals' Equity Ratio peaked at 0.10 during Q1 2022, and registered a low of -0.04 during Q1 2025.
- Its 3-year average for Equity Ratio is -0.01, with a median of -0.02 in 2024.
- In the last 5 years, Amneal Pharmaceuticals' Equity Ratio grew by 13.13% in 2022 and then plummeted by 642.75% in 2024.
- Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Equity Ratio stood at 0.09 in 2021, then tumbled by 48.01% to 0.05 in 2022, then tumbled by 88.10% to 0.01 in 2023, then plummeted by 642.75% to -0.03 in 2024, then decreased by 12.98% to -0.03 in 2025.
- Its Equity Ratio stands at -0.03 for Q3 2025, versus -0.03 for Q2 2025 and -0.04 for Q1 2025.